In recent years, CRISPR-Cas toolboxes have been adapted to target VEGFA for the treatment of AMD, among which CRISPR-Cas9 has been successfully used by multiple groups to disrupt Vegfa in mouse models of laser-induced choroidal neovascularization (CNV)22–25. This evidence concerns the gene VEGFA and age-related macular degeneration.